5:6-Benzindan-2-carbonsaeure | 209224-99-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5:6-Benzindan-2-carbonsaeure
• 英文别名: 2,3-dihydro-1H-cyclopenta[b]naphthalene-2-carboxylic acid；2,3-Dihydro-1H-benz[f]indene-2-carboxylic acid
• CAS: 209224-99-7
• 化学式: C₁₄H₁₂O₂
• 分子量: 212.248
• InChiKey: KRUOUYPQVDGVCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PYRAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0945438A1

  公开（公告）日：1999-09-29

  The present invention relates to a compound represented by the general formula [I]: wherein A and B rings are ortho-condensed to each other, A ring represents an aromatic carbocyclic or heterocyclic ring and B ring represents an aliphatic four- to seven-membered carbocyclic or nitrogen-containing heterocyclic ring, said nitrogen atom being possible to present at only the position where the A ring is condensed; Ar represents an aromatic carbocyclic or heterocyclic ring group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aromatic carbocyclic ring groups; and R represents a substituent selected from the group consisting of a halogen atom and nitro, lower alkyl, lower alkoxy, aromatic carbocyclic ring groups and a carbonyl group having an aromatic carbocyclic ring group, or a hydrogen atom, provided that when the group represented by is the group represented by Ar is not a phenyl group nor a 4-chlorophenyl group, or its salt, a method for its preparation as well as an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.

  本发明涉及通式[I]代表的化合物： 其中 A 环和 B 环彼此正交缩合，A 环代表芳香族碳环或杂环，B 环代表脂肪族四至七元碳环或含氮杂环，所述氮原子可能仅存在于 A 环缩合的位置；Ar 代表芳香碳环或杂环基团，其取代基可选自由卤素原子、低级烷基、低级烯基、低级卤代烷基、低级烷氧基、低级烷硫基、低级烷氨基、低级二烷基氨基和芳香碳环基团组成的组；和 R 代表选自卤素原子和硝基、低级烷基、低级烷氧基、芳香族碳环基团和具有芳香族碳环基团的羰基或氢原子的取代基，条件是当由 代表的基团 Ar 不是苯基，也不是 4-氯苯基、 或其盐，其制备方法以及治疗暴食症、肥胖症或糖尿病的药物，其活性成分均包含该物质。
• US6057335A
  申请人：——

  公开号：US6057335A

  公开（公告）日：2000-05-02